This portfolio reflects Lillys strategy of pursuing multiple complementary approaches to metabolic disease: Tirzepatide : Dual GIP/GLP-1 agonist (approved, injectable) Retatrutide : Triple GIP/GLP-1/glucagon agonist (Phase 3, injectable) Orforglipron : Oral GLP-1R agonist (Phase 3, oral) If retatrutide is approved, it could be positioned as a more potent option for patients requiring greater weight loss or those with MASLD, while tirzepatide and orforglipron serve other patient segments
Some people may experience slight discomfort, such as a cool sensation at the injection site or mild nausea, which typically resolves after the session
Chronic injury, larger animal species, sham-injection controls beyond saline, and pre-registered analysis plans are uncommon in the corpus
For the short-term MIA model, 120 animals were divided into seven groups: saline/vehicle group (n = 19 mice), MIA/vehicle group (n = 18), all MIA/liraglutide groups (n = 17), and dexamethasone group (n = 15)
Sophie Dix (BSc, PhD) Published: 17 June 2025 | Updated: 7 May 2026 Updated: 7 May 2026 Reading time: 8 minutes Quick navigation: Article Summary: What is titration
